Aspirin & Cancer: Spread Prevention Discovery
- A new study, primarily funded by the Medical Research Council and published in Nature, has shed light on how aspirin could possibly reduce the spread of some...
- Researchers at the University of Cambridge made the revelation while investigating metastasis, the process by which cancer spreads.They noted that metastasis accounts for 90% of cancer-related deaths.
- The study revealed that a protein called ARHGEF1 suppresses T cells, a type of immune cell that can eliminate metastatic cancer cells.
Aspirin may revolutionize cancer treatment by perhaps reducing its ability to spread, a revelation recently highlighted in a study published in Nature. This research details how aspirin, our primarykeyword, might combat cancer‘s secondarykeyword, by boosting the immune system. Scientists have identified the process involving thromboxane A2 (TXA2), a key clotting factor, offering insight into aspirin’s anti-metastatic properties. These findings could lead to new treatments or the targeted use of aspirin. News Directory 3 is following the development of ongoing clinical trials.For those considering aspirin, consult with your doctor as side effects are possible. Discover what’s next about this promising research!
Aspirin’s Role in Halting Cancer Metastasis: New Study Unveils Mechanism
Updated June 20, 2025
A new study, primarily funded by the Medical Research Council and published in Nature, has shed light on how aspirin could possibly reduce the spread of some cancers by stimulating the body’s immune system. The research pinpoints a specific mechanism, which scientists believe will bolster ongoing clinical trials and could lead to targeted aspirin use or the development of new drugs to prevent cancer metastasis.
Researchers at the University of Cambridge made the revelation while investigating metastasis, the process by which cancer spreads.They noted that metastasis accounts for 90% of cancer-related deaths. The team focused on how the immune system responds when cancer cells break away from a primary tumor, making them vulnerable to immune attack.
The study revealed that a protein called ARHGEF1 suppresses T cells, a type of immune cell that can eliminate metastatic cancer cells. Further inquiry showed that ARHGEF1 is activated when T cells are exposed to thromboxane A2 (TXA2), a clotting factor. Aspirin reduces TXA2 production, thus releasing T cells from suppression and hindering cancer spread. Experiments using mice with melanoma demonstrated that aspirin reduced metastasis by freeing T cells from TXA2 suppression.
The scientists caution that aspirin can have serious side effects for some individuals. they advise consulting a doctor before starting daily aspirin, as clinical trials are underway to determine safe and effective usage for cancer prevention.
“It was a Eureka moment when we found TXA2 was the molecular signal that activates this suppressive effect on T cells,” said Dr. Jie Yang, a researcher at the University of Cambridge. “Before this, we had not been aware of the implication of our findings in understanding the anti-metastatic activity of aspirin. It was an entirely unexpected finding which sent us down quite a different path of enquiry than we had anticipated.”
Previous studies have indicated that low-dose aspirin may reduce the spread of certain cancers, including breast, bowel, and prostate cancers. This led to the current clinical trials, though the exact mechanism remained unclear until now.
Rahul roychoudhuri, a professor from the University of cambridge who led the study, noted the potential for therapies targeting this early vulnerability to prevent cancer recurrence. He added that aspirin, or similar drugs, could be a more affordable and globally accessible option compared to antibody-based therapies.
What’s next
Researchers plan to collaborate with Professor Ruth Langley at University College london’s MRC Clinical Trials unit, who leads the Add-Aspirin clinical trial. The goal is to determine if aspirin can prevent or delay the recurrence of early-stage cancers. Langley, who was not involved in the current study, called the discovery important, saying it will help interpret ongoing trial results and identify individuals most likely to benefit from aspirin after a cancer diagnosis.